<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1506222202
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2016
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        MEMAXIA 10 mg film-coated tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        MEMANTINE HYDROCHLORIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        91.1
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jamjoom Pharmaceuticals Factory Company" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory Company
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 394]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            JAMJOOM PHARMACEUTICALS CO. LTD.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory  Company
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N06DX01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>How does Memaxia&trade; work<br />Memaxia&trade; belongs to a group of medicines known as anti-dementia medicines.<br />Memory loss in Alzheimer&rsquo;s disease is due to a disturbance of message signals in the<br />brain. The brain contains so-called N-methyl-D-aspartate (NMDA)-receptors that are<br />involved in transmitting nerve signals important in learning and memory. Memaxia&trade;<br />belongs to a group of medicines called NMDA- receptor antagonists. Memaxia&trade; acts<br />on these NMDA-receptors improving the transmission of nerve signals and the memory.</p><p>What is Memaxia&trade; used for<br />Memaxia&trade; is used for the treatment of patients with moderate to severe Alzheimer&rsquo;s<br />disease.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take Memaxia&trade;<br />- if you are allergic (hypersensitive) to memantine hydrochloride or any of the other<br />ingredients of Memaxia&trade; film-coated tablets (see section 6).<br />Warning and precautions<br />Talk to your doctor or pharmacist before taking Memaxia&trade;<br />- if you have a history of epileptic seizures.<br />- if you have recently experienced a myocardial infarction (heart attack), or if you are<br />suffering from congestive heart failure or from an uncontrolled hypertension (high<br />blood pressure).<br />In these situations the treatment should be carefully supervised, and the clinical benefit<br />of Memaxia&trade; reassessed by your doctor on a regular basis.<br />If you suffer from renal impairment (kidney problems), your doctor should closely<br />monitor your kidney function and if necessary adapt the memantine doses accordingly.<br />The use of medicinal products called amantadine (for the treatment of Parkinson&rsquo;s<br />disease), ketamine (a substance generally used as an anaesthetic), dextromethorphan<br />(generally used to treat cough) and other NMDA-antagonists at the same time should be<br />avoided.<br />Memaxia&trade; is not recommended for children and adolescents under the age of 18 years.<br />Using other medicines<br />Please tell your doctor or pharmacist if you are taking or have recently taken any other<br />medicines, including medicines obtained without a prescription.<br />In particular, Memaxia&trade; may change the effects of the following medicines and<br />their dose may need to be adjusted by your doctor:<br />amantadine, ketamine, dextromethorphan<br />dantrolene, baclofen<br />cimetidine, ranitidine, procainamide, quinidine, quinine, nicotine<br />hydrochlorothiazide (or any combination with hydrochlorothiazide)<br />anticholinergics (substances generally used to treat movement disorders or intestinal<br />cramps)<br />anticonvulsants (substances used to prevent and relieve seizures)<br />barbiturates (substances generally used to induce sleep)<br />dopaminergic agonists (substances such as L-dopa, bromocriptine)<br />neuroleptics (substances used in the treatment of mental disorders)<br />oral anticoagulants.<br />If you go into hospital, let your doctor know that you are taking Memaxia&trade;.<br />Taking Memaxia&trade; with food and drink<br />You should inform your doctor if you have recently changed or intend to change your<br />diet substantially (e.g. from normal diet to strict vegetarian diet) or if you are suffering<br />from states of renal tubulary acidosis (RTA, an excess of acid-forming substances in the<br />blood due to renal dysfunction (poor kidney function)) or severe infections of the<br />urinary tract (structure that carries urine), as your doctor may need to adjust the dose of<br />your medicine.<br />Pregnancy and breast-feeding<br />Ask your doctor or pharmacist for advice before taking any medicine.<br />Tell your doctor if you are pregnant or planning to become pregnant. The use of<br />memantine in pregnant women is not recommended.<br />Women taking Memaxia&trade; should not breast-feed.<br />Driving and using machines<br />Your doctor will tell you whether your illness allows you to drive and to use machines<br />safely. Also, Memaxia&trade; may change your reactivity, making driving or operating<br />machinery inappropriate.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take Memaxia&trade; exactly as your doctor has told you. You should check with<br />your doctor or pharmacist if you are not sure.<br />Dosage<br />The recommended dose of Memaxia&trade; for adults and elderly patients is 20 mg once a<br />day. In order to reduce the risk of side effects this dose is achieved gradually by the<br />following daily treatment scheme:<br />week 1 half a 10 mg tablet<br />week 2 one 10 mg tablet<br />week 3 one and a half 10 mg tablets<br />week 4 and beyond two 10 mg tablets once a day<br />The usual starting dose is half a tablet once a day (1x 5 mg) for the first week. This is<br />increased to one tablet once a day (1x 10 mg) in the second week and to 1 and a half<br />tablets once a day in the third week. From the fourth week on, the usual dose is 2 tablets<br />once a day (1x 20 mg).<br />Dosage in patients with impaired kidney function<br />If you have impaired kidney function, your doctor will decide upon a dose that suits<br />your condition. In this case, monitoring of your kidney function should be performed by<br />your doctor at specified intervals.</p><p>Administration<br />Memaxia&trade; should be administered orally once a day. To benefit from your medicine you<br />should take it regularly every day at the same time of the day. The tablets should be<br />swallowed with some water. The tablets can be taken with or without food.<br />Duration of treatment<br />Continue to take Memaxia&trade; as long as it is of benefit to you. Your doctor should assess<br />your treatment on a regular basis.<br />If you take more Memaxia&trade; than you should<br />- In general, taking too much Memaxia&trade; should not result in any harm to you. You may<br />experience increased symptoms as described in section 4. &ldquo;Possible side effects&rdquo;.<br />- If you take a large overdose of Memaxia&trade;, contact your doctor or get medical advice,<br />as you may need medical attention.<br />If you forget to take Memaxia&trade;<br />- If you find you have forgotten to take your dose of Memaxia&trade;, wait and take your next<br />dose at the usual time.<br />- Do not take a double dose to make up for a forgotten dose.<br />If you have any further questions on the use of this product, ask your doctor or<br />pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, This medicine can cause side effects, although not everybody gets<br />them. In general, the observed side effects are mild to moderate.<br />Common (affects 1 to 10 users in 100):<br />&middot; Headache, sleepiness, constipation, elevated liver function tests, dizziness, balance<br />disorders, shortness of breath, high blood pressure and drug hypersensitivity<br />Uncommon (affects 1 to 10 users in 1,000):<br />&middot; Tiredness, fungal infections, confusion, hallucinations, vomiting, abnormal gait, heart<br />failure and venous blood clotting (thrombosis/thromboembolism)<br />Very Rare (affects less than 1 user in 10,000):<br />&middot; Seizures<br />Not known (frequency cannot be estimated from the available data):<br />&middot; Inflammation of the pancreas, inflammation of the liver (hepatitis) and psychotic<br />reactions<br />Alzheimer&rsquo;s disease has been associated with depression, suicidal ideation and suicide.<br />These events have been reported in patients treated with Memaxia&trade;.<br />If any of the side effects gets serious, or if you notice any side effects not listed in this<br />leaflet, please tell your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.<br />Do not store above 30 &ordm;C.<br />Do not use Memaxia&trade; after the expiry date which is stated on the carton and the blister<br />after EXP.<br />Medicines should not be disposed of via wastewater or household waste. Ask your<br />pharmacist how to dispose of medicines no longer required. These measures will help to<br />protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Memaxia&trade; contains<br />&bull; The active substance is memantine hydrochloride. Each film-coated tablet contains<br />10 mg of memantine hydrochloride equivalent to 8.31 mg of memantine.<br />&bull; The other ingredients are microcrystalline cellulose, croscarmellose sodium, colloidal<br />silicon dioxide, magnesium stearate, all in the tablet core; and opadry OYB (which<br />contains, polyvinyl alcohol, titanium dioxide, talc, soy lecithin &amp; xanthan gum) and iron<br />oxide yellow, all in the tablet coating.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Memaxia™ Tablets 10 mg : Pale yellow to yellow, oval, biconvex, film-coated tablets,
engraved with ‘JP 94’ on one side and break line on other side.
• Memaxia™ Tablets 10 mg available in a box of 30 film-coated tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Jamjoom Pharmaceuticals Co., Ltd., Jeddah, Saudi Arabia.<br />Tel: +966-12-6081111, Fax: +966-12-6081222.<br />Website: www.jamjoompharma.com</p><p>To report any side effect(s):<br />&bull; Saudi Arabia:<br />The National Pharmacovigilance and<br />Drug Safety Centre (NPC)<br />o Fax: +966-11-205-7662<br />o Call NPC at +966-11-2038222,<br />Ext: 2317-2356-2340.<br />o Reporting hotline: 19999<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: www.sfda.gov.sa/npc<br />&bull; Other GCC States:<br />&minus; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                10-05-2023
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>ميماكسيا&nbsp;ينتمي إلى مجموعة من الأدوية تعرف باسم الأدوية المضادة للخرف.</p><p>فقدان الذاكرة في مرض الزهايمر هو نتيجة لإضطراب رسائل الإشارات في الدماغ. يحتوي الدماغ ما يسمى مستقبلات ن-ميثيل - د-اسبارتات&nbsp;(NMDA)التي تشارك في نقل الإشارات العصبية الهامة في التعلم والذاكرة.<br />&nbsp;ميماكسيا ينتمي إلى مجموعة من الأدوية تسمى مضادات مستقبلات(NMDA) ميماكسيا ينتمي يعمل على هذه المستقبلات.<br />&nbsp;المستقبلات (NMDA) ويحسن نقل الإشارات العصبية والذاكرة.</p><p>يستخدم ميماكسيا لعلاج المرضى الذين يعانون من مرض زهايمر متوسط إلى شديد.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تتناول أقراص ميماكسيا</p><p>&bull; إذا كان لديك حساسية من ميمانتين هيدروكلوريد أو لأي من مكونات أقراص ميماكسياالأخرى (أنظر قسم رقم 6)</p><p>التحذيرات و الاحتياطات<br />&nbsp;تحدث إلى طبيبك أو الصيدلي قبل ان تتناول ميماكسيا:</p><p>- إذا كان لديك تاريخ من نوبات الصرع.</p><p>- إذا واجهت مؤخراً احتشاء عضلة القلب (نوبة قلبية)، أو إذا كنت تعاني من قصور القلب الاحتقاني أو ارتفاع ضغط الدم غير المنضبط .</p><p>في هذه الحالات يجب أن يكون العلاج تحت إشراف بعناية، و الفائدة السريرية من ميماكسيا&nbsp;سيتم إعادة تقييمها من قبل الطبيب على أساس منتظم.<br />إذا كنت تعاني من القصور الكلوي (مشاكل في الكلى)، يجب أن يرصد طبيبك عن كثب وظيفة الكلى الخاصة<br />بك وإذا لزم الأمر ضبط جرعة ميمانتين وفقا لذلك.<br />يجب تجنب استخدام أدوية طبية تدعى أمانتادين (لعلاج مرض باركنسون)، كيتامين (مادة تستخدم عادة كمخدر)، ديكسترومثورفان (تستخدم عادة لعلاج السعال) وغيرها من مضادات مستقبلات (NMDA) في نفس الوقت.</p><p>لا ينصح بإستخدام ميماكسيا&nbsp;للأطفال والمراهقين دون سن ۱۸ عاما.</p><p>إستخدام أدوية أخرى<br />يرجى إخبار الطبيب أو الصيدلي إذا كنت تتناول أو تناولت مؤخراً أي أدوية أخرى، بما في ذلك الأدوية التي تم<br />الحصول عليها دون وصفة طبية.<br />فعالية الأدوية التالية و قد تحتاج الجرعة إلى تعديل من قبل &trade; على وجه الخصوص، قد تغيير ميماكسيا<br />الطبيب:<br />أمانتادين، كيتامين، ديكسترومثورفان<br />دانترولين، باكلوفين<br />سيميتيدين، رانيتيدين، بروكاييناميد، كينيدين، كينين، نيكوتين<br />هيدروكلوروثيازيد (أو أي تركيبة مع هيدروكلوروثيازيد)<br />مضادات الكولين (مواد تستخدم عادة لعلاج اضطرابات الحركة أو التقلصات المعوية)<br />مضادات الاختلاج (مواد تستخدم لمنع وتخفيف التشنجات)<br />الباربيتورات (مواد تستخدم عادة للحث على النوم)<br />مستقبلات الدوبامين (المواد مثل إل-دوبا، بروموكريبتين)<br />مضادات الذهان (المواد المستخدمة في علاج الاضطرابات النفسية)<br />مضادات التخثر الفموية.<br />.&trade; إذا ذهبت إلى المستشفى، أخبر الطبيب بأنك تتناول ميماكسيا<br />مع الطعام والشراب &trade; تناول ميماكسيا<br />يجب عليك إبلاغ الطبيب إذا كنت قد غيرت مؤخرا أو تنوي تغيير النظام الغذائي الخاص بك بشكل كبير (على<br />سبيل المثال من النظام الغذائي العادي إلى نظام غذائي نباتي صارم) أو إذا كنت تعاني من حالات حماض<br />كلوي نبيبي [ وجود فائض من المواد المكونة للحمض في الدم بسبب الفشل الكلوي (ضعف وظيفة الكلى)] أو<br />التهابات حادة في المسالك البولية ، حيث أن طبيبك قد يحتاج إلى ضبط جرعتك من الدواء.<br />الحمل و الرضاعة<br />إسألى طبيبك أو الصيدلي للحصول على المشورة قبل تناول أي دواء.<br />أخبرى طبيبك إذا كنتِ حاملا أو تخططين للحمل. لا ينصح باستخدام ميمانتين في النساء الحوامل.<br />لا ينبغي أن يٌرضعن. &trade; النساء اللواتي يتناولن ميماكسيا<br />قيادة المركبات و تشغيل الآلات<br />سيخبرك طبيبك إذا ما كان مرضك يسمح لك بالقيادة واستخدام الآلات بأمان.<br />رد فعلك ، مما يجعل القيادة أو تشغيل الآلات غير مناسبة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>قم دائما بتناول ميماكسيا&nbsp;كما أخبرك طبيبك تماما. يجب عليك مراجعة طبيبك أو الصيدلى الخاص بك إذا كنت&nbsp;غير متأكد من طريقة الاستخدام</p><p>الجرعة</p><p>للبالغين والمرضى المسنين هي ۲۰ ملجم مرة واحدة يومياً. و من أجل الحد&nbsp;من خطر الآثار الجانبية يتم تحقيق هذه الجرعة تدريجياً بإتباع نظام العلاج اليومي التالي:</p><p>الأسبوع الأول نصف قرص ۱۰ ملجم<br />الأسبوع الثانى قرص واحد ۱۰ ملجم<br />الأسبوع الثالث قرص ونصف ۱۰ ملجم<br />الأسبوع الرابع وما بعده قرصين ۱۰ ملجم مرة واحدة يومياً</p><p>جرعة البداية المعتادة هي نصف قرص مرة واحدة يومياً&nbsp;في الأسبوع الأول. يتم زيادتها&nbsp;إلى قرص واحد مرة واحدة يومياً&nbsp;في الأسبوع الثاني ثم إلي قرص ونصف مرة واحدة&nbsp;يومياً في الأسبوع الثالث. من الأسبوع الرابع، الجرعة المعتادة هي قرصين مرة واحدة يومياً.</p><p>الجرعة في المرضى الذين يعانون من اختلال وظائف الكلى</p><p>ذا كان لديك اختلال في وظائف الكلى، سيقرر طبيبك الجرعة التي تناسب حالتك. و في هذه الحالة، يجب أن يتم رصد وظيفة الكلى الخاصة بك من قبل الطبيب في فترات زمنية محددة.</p><p>طريقة الإستخدام<br />بالفم مرة واحدة يومياً. للاستفادة من الدواء يجب تناوله بانتظام يومياً في نفس &trade; ينبغي أن تناول ميماكسيا<br />الوقت من اليوم. يجب ابتلاع الأقراص مع بعض الماء. يمكن تناول الأقراص مع أو بدون الطعام.</p><p>مدة العلاج<br />طالما أنها ذات فائدة لك. وينبغي أن يقيم طبيبك العلاج على أساس منتظم. &trade; إستمر في تناول ميماكسيا<br />أكثر مما يجب &trade; إذا تناولت ميماكسيا<br />لا ينبغي أن يؤدي إلى أي ضرر لك. قد تواجهه زيادة الأعراض &trade; - بصفة عامة، تناول الكثير من ميماكسيا<br />الموضحة في القسم ٤. &quot;الآثار الجانبية المحتملة&quot;.<br />اتصل بطبيبك أو أحصل على المشورة الطبية، حيث ،&trade; - إذا كنت تناولت جرعة زائدة كبيرة من ميماكسيا<br />قد تحتاج إلى عناية طبية.<br />&trade; إذا كنت قد نسيت أن تتناول ميماكسيا<br />إنتظر و تناول الجرعة التالية في الوقت المعتاد. ،&trade; - إذا وجدت أنك قد نسيت أن تتناول جرعة من ميماكسيا<br />- لا تتناول جرعة مضاعفة لتعويض الجرعة المنسية.<br />إذا كان لديك أي أسئلة أخرى عن استخدام هذا الدواء، إسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية، يمكن أن يسبب هذا الدواء آثار جانبية، على الرغم أنها لا تحدث مع الجميع.<br />بشكل عام، فإن الآثار الجانبية الملحوظة هي خفيفة الى معتدلة.</p><p>شائعة ( تؤثر على ۱ إلى ۱۰ في كل ۱۰۰ مستخدم ):<br />&bull; صداع، نعاس، إمساك، ارتفاع اختبارات وظائف الكبد، دوخة، اضطرابات التوازن، ضيق في التنفس، ارتفاع<br />ضغط الدم وفرط الحساسية للدواء.<br />غير شائعة ( تؤثر على ۱ إلى ۱۰ في كل ۱۰۰۰ مستخدم ):<br />&bull; تعب، عدوى فطرية، ارتباك، هلوسة، تقيؤ، مشية غير طبيعية، فشل القلب وتخثر الدم الوريدي (الجلطة /<br />انصمام خثارى)<br />نادر جدا (يؤثر على أقل من ۱ في كل ۱۰,۰۰۰ مستخدم ):<br />&bull; نوبات<br />غير معروفة (لا يمكن تقدير ترددها من البيانات المتاحة):<br />&bull; التهاب البنكرياس، التهاب الكبد وردود الفعل النفسية.<br />ارتبط مرض الزهايمر بالاكتئاب، التفكير في الانتحار والانتحار. وقد تم الإبلاغ عن هذه الأحداث مع المرضى<br />.&trade; المعالجين بميماكسيا<br />إذا أصبح أي من الآثار الجانبية أكثر حدة، أو إذا لاحظت أي آثار جانبية غير المذكورة في هذه النشرة، يرجى<br />إخبار الطبيب أو الصيدلي.<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يحفظ بعيداً عن متناول و مرأى الأطفال.<br />يحفظ في درجة حرارة لا تزيد عن ۳۰ درجة مئوية.<br />لا تقم بإستخدام ميماكسيا بعد انتهاء تاريخ الصلاحية المطبوع على العبوة و الشرائط.&nbsp;&nbsp;<br />لا يتم التخلص من الأدوية عن طريق مياه الصرف أو النفايات المنزلية. إسأل الصيدلي عن طريقة التخلص من<br />الأدوية الغير مرغوب فيها فسوف تساعد هذه الإجراءات على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&bull; المادة الفعالة هي ميمانتين هيدروكلوريد.<br />كل قرص مغلف يحتوى على ۱۰ ملجم من ميمانتين هيدروكلوريد يعادل ۸٫۳۱ ملجم ميمانتين.</p><p>&bull; المكونات الأخرى سليلوز جريزوفولفين، كروسكرميلوز الصوديوم، ثاني أكسيد السيليكون الغروى، ستيرات<br />الذي يحتوي على كحول بولي فينيل، ثاني أكسيد ) OYB الماغنيسيوم، وكلها في داخل القرص؛ و أوبادرى<br />التيتانيوم، تلك، فول الصويا، الليسيثين و صمغ زنتان) و أكسيد الحديد الأصفر، وكلها في غلاف القرص.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:right">ميماكسيا ۱۰ ملجم أقراص: لونها أصفر فاتح إلى أصفر، بيضاوية، ثنائية التحدب ، مغلفة، محفور(JP 94)على جانب واحد و خط للكسر على الجانب الآخر.</p><p style="text-align:right">ميماكسيا۱۰&nbsp;ملجم أقراص، متوفرة فى عبوة تحتوي على ۳۰ قرص مغلف.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>شركة مصنع جمجوم للأدویة، جدة، المملكة العربیة السعودیة.<br />+۹٦٦-۱۲- ۹٦٦ + فاكس: ٦۰۸۱۲۲۲ -۱۲- الھاتف: ٦۰۸۱۱۱۱<br />www.jamjoompharma.com : الموقع الإلكتروني<br />للإبلاغ عن أي أثار جانبیھ:<br />&bull; المملكة العربیة السعودیة:<br />- المركز الوطني للتیقظ و السلامة الدوائیة<br />+۹٦٦-۱۱-۲۰٥- فاكس: ۷٦٦۲ o<br />للإتصال بالإدارة التنفیذیة للتیقظ وإدارة الأزمات. o<br />+۹٦٦-۱۱- ھاتف: ۲۰۳۸۲۲۲ o<br />۲۳٤۰-۲۳٥٦- تحویلة: ۲۳۱۷<br />الخط الساخن للإبلاغ: ۱۹۹۹۹ o<br />npc.drug@sfda.gov.sa : برید إلكتروني o<br />www.sfda.gov.sa/npc : الموقع الإلكتروني o<br />&bull; دول الخلیج الأخرى:<br />الرجاء الاتصال بالمؤسسات و الھیئات الوطنیة في كل دولة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            10-05-2023
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Memaxia 10 mg Film Coated Tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains 10 mg of Memantine hydrochloride equivalent to 8.31 mg
Memantine.
For full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The 10 mg film-coated tablets are Pale yellow to yellow, oval, biconvex, film coated tablets,
engraved with `JP 94' on one side and break line on other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of adult patients with moderate to severe Alzheimer&#39;s disease.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment should be initiated and supervised by a physician experienced in the diagnosis and<br />treatment of Alzheimer&#39;s dementia.</p><p><strong><u>Posology</u></strong></p><p>Therapy should only be started if a caregiver is available who will regularly monitor the intake of the medicinal product by the patient. Diagnosis should be made according to current guidelines. The tolerance and dosing of Memantine should be reassessed on a regular basis, preferably within three months after start of treatment. Thereafter, the clinical benefit of Memantine and the patient&#39;s tolerance of treatment should be reassessed on a r egular basis according to current clinical guidelines. Maintenance treatment can be continued for as long as a therapeutic benefit is favorable and the patient tolerates treatment with Memantine. Discontinuation of Memantine should be considered when evidence of a therapeutic effect is no l onger present or if the patient does not tolerate treatment.</p><p><strong><u>Dosage</u></strong></p><p>The recommended starting dose is 5 mg per day, which is stepwise increased over the first 4 weeks of treatment reaching the recommended maintenance dose as follows:</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td style="width:205px">week 1</td><td style="width:293px">half a 10 mg tablet</td></tr><tr><td style="width:205px">week 2</td><td style="width:293px">one 10 mg tablet</td></tr><tr><td style="width:205px">week 3</td><td style="width:293px">one and a half 10 mg tablets</td></tr><tr><td style="width:205px">week 4 and beyond</td><td style="width:293px">two 10 mg tablets once a day</td></tr></tbody></table><p><br />The usual starting dose is half a tablet once a day (1x 5 mg) for the ﬁrst week. This is increased to one tablet once a day (1x 10 mg) in the second week and to 1 and a half tablets once a day in the third week. From the fourth week on, the usual dose is 2 tablets once a day (1x 20 mg).</p><p>Maintenance dose</p><p>The recommended maintenance dose is 20 mg per day.</p><p><em>Elderly</em></p><p>On the basis of the clinical studies, the recommended dose for patients over the age of 65 years is 20 mg per day (one 20 mg film-coated tablet/two 10 mg film-coated tablets) as described above.</p><p><em>Renal impairment</em></p><p>In patients with mildly impaired renal function (creatinine clearance 50 &ndash; 80 ml/min) no dos e adjustment is required. In patients with moderate renal impairment (creatinine clearance 30 &ndash; 49 ml/min) daily dose should be 10 mg (one 10 mg film-coated tablet) per day. If tolerated well after&nbsp; at least 7 days of treatment, the dose could be increased up to 20 mg/day according to standard titration scheme. In patients with severe renal impairment (creatinine clearance 5 &ndash; 29 ml/min) daily dose should be 10 mg (one 10 mg film-coated tablet) per day.</p><p><em>Hepatic impairment</em></p><p>In patients with mild or moderate hepatic impaired function (Child-Pugh A and Child-Pugh B), no dose adjustment is needed. No data on the use of Memantine in patients with severe hepatic impairment are available. Administration of Memaxia is not recommended in patients with severe hepatic impairment.</p><p><em>Paediatric population</em></p><p>No data available.</p><p><u>Method of administration</u></p><p>Memaxia tablets should be administered orally once a day and should be taken at the same time every day. The film-coated tablets can be taken with or without food.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Caution is recommended in patients with epilepsy, former history of convulsions or patients with predisposing factors for epilepsy.</p><p>Concomitant use of N-methyl-D-aspartate (NMDA)-antagonists such as amantadine, ketamine or dextromethorphan should be avoided. These compounds act at the same receptor system as memantine, and therefore adverse reactions (mainly central nervous system (CNS)-related) may be more frequent or more pronounced.</p><p>Some factors that may raise urine pH may necessitate careful monitoring of the patient. These factors include drastic changes in diet, e.g. from a carnivore to a v egetarian diet, or a m assive ingestion of alkalising gastric buffers. Also, urine pH may be elevated by states of renal tubulary acidosis (RTA) or severe infections of the urinary tract with <em>Proteus </em>bacteria.</p><p>In most clinical trials, patients with recent myocardial infarction, uncompensated congestive heart failure (NYHA III-IV), or uncontrolled hypertension were excluded. As a consequence, only limited data are available and patients with these conditions should be closely supervised.</p><p><em>Excipients: </em>The oral solution contains sorbitol. Patients with rare hereditary problems of fructose intolerance should not take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Due to the pharmacological effects and the mechanism of action of Memantine the following interactions may occur:</p><p>&bull;&nbsp; The mode of action suggests that the effects of L-dopa, dopaminergic agonists, and anticholinergics may be enhanced by concomitant treatment with NMDA-antagonists such as memantine. The effects of barbiturates and neuroleptics may be reduced. Concomitant administration of memantine with the antispasmodic agents, dantrolene or baclofen, can modify their effects and a dose adjustment may be necessary.</p><p>&bull;&nbsp; Concomitant use of memantine and amantadine should be avoided, owing to the risk of pharmacotoxic psychosis. Both compounds are chemically related NMDA-antagonists. The same may be true for ketamine and dextromethorphan. There is one published case report on a possible risk also for the combination of memantine and phenytoin.</p><p>&bull; Other active substances such as cimetidine, ranitidine, procainamide, quinidine, quinine and nicotine that use the same renal cationic transport system as amantadine may also possibly interact with memantine leading to a potential risk of increased plasma levels.</p><p>&bull;&nbsp; There may be a possibility of reduced serum level of hydrochlorothiazide (HCT) when memantine is co-administered with HCT or any combination with HCT.</p><p>&bull; In post-marketing experience, isolated cases with international normalized ratio (INR) increases have been reported in patients concomitantly treated with warfarin. Although no causal relationship has been established, close monitoring of prothrombin time or INR is advisable for patients concomitantly treated with oral anticoagulants.</p><p>In single-dose pharmacokinetic (PK) studies in young healthy subjects, no r elevant active substance-active substance interaction of memantine with glyburide/metformin or donepezil was observed.</p><p>In a clinical study in young healthy subjects, no r elevant effect of memantine on the pharmacokinetics of galantamine was observed.</p><p>Memantine did not inhibit CYP 1A2, 2A6, 2C9, 2D6, 2E1, 3A, flavin containing monooxygenase, epoxide hydrolase or sulphation <em>in vitro</em>.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Pregnancy Category B<br />Studies in pregnant women, however, have not shown that Memantine increases the risk of<br />abnormalities when administered during the first {second, third, or all} trimester(s) of pregnancy.<br />Despite the animal findings, it would appear that the possibility of fetal harm is remote, if the drug<br />is used during pregnancy. Nevertheless, because the studies in humans cannot rule out the<br />possibility of harm, Memantine should be used during pregnancy only if clearly needed&rdquo;.<br />Pregnancy: There are no or limited amount of data from the use of Memantine in pregnant women.<br />Animal studies indicate a potential for reducing intrauterine growth at exposure levels, which are<br />identical or slightly higher than at human exposure. The potential risk for humans is unknown.<br />Memantine should not be used during pregnancy unless clearly necessary.<br />Breast-feeding: It is not known whether Memantine is excreted in human breast milk but, taking<br />into consideration the lipophilicity of the substance, this probably occurs. Women taking<br />Memantine should not breast-feed.<br />Fertility: No adverse reactions of Memantine were noted on male and female fertility.</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Moderate to severe Alzheimer&#39;s disease usually causes impairment of driving performance and compromises the ability to use machinery. Furthermore, Memaxia has minor to moderate influence on the ability to drive and use machines such that outpatients should be warned to take special care.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary of the safety profile<br />In clinical trials in mild to severe dementia, involving 1,784 patients treated with Memantine and<br />1,595 patients treated with placebo, the overall incidence rate of adverse reactions with Memantine<br />did not differ from those with placebo; the adverse reactions were usually mild to moderate in<br />severity. The most frequently occurring adverse reactions with a higher incidence in the Memantine<br />group than in the placebo group were dizziness (6.3% vs 5.6%, respectively), headache (5.2% vs<br />3.9%), constipation (4.6% vs 2.6%), somnolence (3.4% vs 2.2%) and hypertension (4.1% vs 2.8%).<br />Tabulated list of adverse reactions<br />The following Adverse Reactions listed in the Table below have been accumulated in clinical<br />studies with Memaxia and since its introduction in the market.<br />Adverse reactions are ranked according to system organ class, using the following convention: very<br />common (&ge;1/10), common (&ge;1/100 to &lt; 1/10), uncommon (&ge; 1/1,000 to &lt; 1/100), rare (&ge;1/10,000<br />to &lt; 1/1,000), very rare (&lt; 1/10,000), not known (cannot be estimated from the available data).<br />Within each frequency grouping, undesirable effects are presented in order of decreasing<br />seriousness.</p><p><img alt="" width="1083" height="777" src="data:image/png;base64,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" /></p><p>1 Hallucinations have mainly been observed in patients with severe Alzheimer&#39;s disease.</p><p>2 Isolated cases reported in post-marketing experience.</p><p>&nbsp;</p><p>Alzheimer&#39;s disease has been associated with depression, suicidal ideation and suicide. In post- marketing experience these reactions have been reported in patients treated with Memantine.</p><p>&nbsp;</p><p>To report any side effect(s):<br />&bull; Saudi Arabia:<br />The National Pharmacovigilance and Drug Safety Centre (NPC)<br />&bull; Fax: +966-11-205-7662<br />&bull; Call NPC at +966-11-2038222,<br />Exts: 2317-2356-2353-2354-2334-2340.<br />&bull; Toll free phone: 19999<br />&bull; E-mail: npc.drug@sfda.gov.sa<br />&bull; Website: www.sfda.gov.sa/npc<br />&bull; Other GCC States:<br />&minus; Please contact the relevant competent authority</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Only limited experience with overdose is available from clinical studies and post-marketing experience.</p><p><u>Symptoms</u></p><p>Relative large overdoses (200 mg and 105 mg/day for 3 days, respectively) have been associated with either only symptoms of tiredness, weakness and/or diarrhoea or no symptoms. In the overdose cases below 140 m g or unknown dose the patients revealed symptoms from central nervous system (confusion, drowsiness, somnolence, vertigo, agitation, aggression, hallucination, and gait disturbance) and/or of gastrointestinal origin (vomiting and diarrhoea).</p><p>In the most extreme case of overdose, the patient survived the oral intake of a total of 2000 mg memantine with effects on the central nervous system (coma for 10 days, and later diplopia and agitation). The patient received symptomatic treatment and plasmapheresis. The patient recovered without permanent sequelae.</p><p>In another case of a large overdose, the patient also survived and recovered. The patient had received 400 mg memantine orally. The patient experienced central nervous system symptoms such as restlessness, psychosis, visual hallucinations, proconvulsiveness, somnolence, stupor, and unconsciousness.</p><p><u>Treatment</u></p><p>In the event of overdose, treatment should be symptomatic. No specific antidote for intoxication or overdose is available. Standard clinical procedures to remove active substance material, e.g. gastric lavage, carbo medicinalis (interruption of potential entero-hepatic recirculation), acidification of urine, forced diuresis should be used as appropriate.</p><p>In case of signs and symptoms of general central nervous system (CNS) overstimulation, careful symptomatic clinical treatment should be considered.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Psychoanaleptics. Other Anti-dementia drugs, ATC code: N06DX01. There is increasing evidence that malfunctioning of glutamatergic neurotransmission, in particular at NMDA-receptors, contributes to both expression of symptoms and disease progression in neurodegenerative dementia.</p><p>Memantine is a voltage-dependent, moderate-affinity uncompetitive NMDA-receptor antagonist. It modulates the effects of pathologically elevated tonic levels of glutamate that may lead to neuronal dysfunction.</p><p>Clinical studies<br />A pivotal monotherapy study in a population of patients suffering from moderate to severe<br />Alzheimer&#39;s disease (mini mental state examination (MMSE) total scores at baseline of 3 - 14)<br />included a total of 252 outpatients. The study showed beneficial effects of memantine treatment in<br />comparison to placebo at 6 months (observed cases analysis for the clinician&acute;s interview based<br />impression of change (CIBIC-plus): p=0.025; Alzheimer&#39;s disease cooperative study &ndash; activities of<br />daily living (ADCS-ADLsev): p=0.003; severe impairment battery (SIB): p=0.002).<br />A pivotal monotherapy study of memantine in the treatment of mild to moderate Alzheimer&#39;s<br />disease (MMSE total scores at baseline of 10 to 22) included 403 patients. Memantine-treated<br />patients showed a statistically significantly better effect than placebo-treated patients on the<br />primary endpoints: Alzheimer&#39;s disease assessment scale (ADAS-cog) (p=0.003) and CIBIC-plus<br />(p=0.004) at week 24 (last observation carried forward (LOCF)). In another monotherapy study in<br />mild to moderate Alzheimer&#39;s disease a total of 470 patients (MMSE total scores at baseline of 11-<br />23) were randomised. In the prospectively defined primary analysis statistical significance was not<br />reached at the primary efficacy endpoint at week 24.<br />A meta-analysis of patients with moderate to severe Alzheimer&#39;s disease (MMSE total scores &lt; 20)<br />from the six phase III, placebo-controlled, 6-month studies (including monotherapy studies and<br />studies with patients on a stable dose of acetylcholinesterase inhibitors) showed that there was a<br />statistically significant effect in favour of Memantine treatment for the cognitive, global, and<br />functional domains. When patients were identified with concurrent worsening in all three domains,<br />results showed a statistically significant effect of Memantine in preventing worsening, as twice as<br />many placebo-treated patients as Memantine-treated patients showed worsening in all three<br />domains (21% vs. 11%, p&lt;0.0001).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Memantine has an absolute bioavailability of approximately 100%. T<sub>max</sub> is between 3 and 8 hours. There is no indication that food influences the absorption of Memantine.</p><p><u>Distribution</u></p><p>Daily doses of 20 mg lead to steady-state plasma concentrations of Memantine ranging from 70 to 150 ng/ml (0.5 - 1 &micro;mol) with large interindividual variations. When daily doses of 5 t o 30 mg were administered, a mean cerebrospinal fluid (CSF)/serum ratio of 0.52 was calculated. The volume of distribution is around 10 l/kg. About 45% of Memantine is bound to plasma-proteins.</p><p><u>Biotransformation</u></p><p>In man, about 80% of the circulating Memantine-related material is present as the parent compound. Main human metabolites are N-3,5-dimethyl-gludantan, the isomeric mixture of 4- and 6-hydroxy-memantine, and 1-nitroso-3,5-dimethyl-adamantane. None of these metabolites exhibit NMDA-antagonistic activity. No cytochrome P 450 catalysed metabolism has been detected <em>in vitro.</em></p><p>&nbsp;</p><p>In a study using orally administered <sup>14</sup>C-memantine, a mean of 84% of the dose was recovered within 20 days, more than 99% being excreted renally.</p><p><u>Elimination</u></p><p>Memantine is eliminated in a monoexponential manner with a terminal t<sub>&frac12;</sub> of 60 to 100 hours. In volunteers with normal kidney function, total clearance (Cl<sub>tot</sub>) amounts to 170 ml/min/1.73 m&sup2; and part of total renal clearance is achieved by tubular secretion.</p><p>Renal handling also involves tubular reabsorption, probably mediated by cation transport proteins. The renal elimination rate of memantine under alkaline urine conditions may be reduced by a factor of 7 to 9 (see section 4.4). Alkalisation of urine may result from drastic changes in diet, e.g. from a carnivore to a vegetarian diet, or from the massive ingestion of alkalising gastric buffers.</p><p><u>Linearity</u></p><p>Studies in volunteers have demonstrated linear pharmacokinetics in the dose range of 10 to 40 mg. <u>Pharmacokinetic/pharmacodynamic relationship</u></p><p>At a dose of Memantine of 20 mg per day the CSF levels match the k<sub>i</sub>-value (k<sub>i</sub> = inhibition constant) of Memantine, which is 0.5 &micro;mol in human frontal cortex.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In short term studies in rats, Memantine like other NMDA-antagonists have induced neuronal vacuolisation and necrosis (Olney lesions) only after doses leading to very high peak serum concentrations. Ataxia and other preclinical signs have preceded the vacuolisation and necrosis. As the effects have neither been observed in long term studies in rodents nor in non-rodents, the clinical relevance of these findings is unknown.</p><p>Ocular changes were inconsistently observed in repeat dose toxicity studies in rodents and dogs, but not in monkeys. Specific ophthalmoscopic examinations in clinical studies with Memantine did not disclose any ocular changes.</p><p>Phospholipidosis in pulmonary macrophages due to accumulation of Memantine in lysosomes was observed in rodents. This effect is known from other active substances with cationic amphiphilic properties. There is a possible relationship between this accumulation and the vacuolisation observed in lungs. This effect was only observed at high doses in rodents. The clinical relevance of these findings is unknown.</p><p>No genotoxicity has been observed following testing of Memantine in standard assays. There was no evidence of any carcinogenicity in lifelong studies in mice and rats. Memantine was not teratogenic in rats and rabbits, even at maternally toxic doses, and no adverse effects of Memantine were noted on fertility. In rats, foetal growth reduction was noted at exposure levels, which are identical or slightly higher than at human exposure.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Core tablet content:</u></p><p>Microcrystalline cellulose, Croscarmellose Sodium, Colloidal Silicon dioxide, Magnesium Stearate.</p><p>&nbsp;</p><p><u>Coating content:</u></p><p>Opadry OYB (which contains polyvinyl alcohol, titanium dioxide, talc, soy lecithin &amp; Xanthan gum) and Iron oxide yellow.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30 &ordm;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Memaxia 10 mg Film Coated Tablets are packed as 10 Tablets in Aluminum-PVC/PVDC blister containing 30 (3x10) film coated tablets in outer carton with Patient Information Leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jamjoom Pharmaceuticals Company Limited
Plot No. ME1:3, Phase V, Industrial City, P.O. Box 6267, Jeddah-21442, Kingdom of Saudi Arabia.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                06/2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>